Quantification of 11 therapeutic kinase inhibitors in human plasma for therapeutic drug monitoring using liquid chromatography coupled with tandem mass spectrometry

Keyphrases

• Therapeutic Drug Monitoring 100%
• Liquid Chromatography-tandem Mass Spectrometry (LC-MS/MS) 100%
• Human Plasma 100%
• Kinase Inhibitor 100%
• Dasatinib 33%
• Erlotinib 33%
• Sunitinib 33%
• Lapatinib 33%
• Sorafenib 33%
• Imatinib 33%
• Vemurafenib 33%
• Nilotinib 33%
• Pazopanib 33%
• Gefitinib 33%
• Method Validation 33%
• N-desethyl Sunitinib 33%
• Clinical Treatment 16%
• Protein Precipitation 16%
• Reversed-phase Chromatography 16%
• Positive Ion Mode 16%
• Tandem Mass Spectrometry 16%
• U.S. Food 16%
• Bioanalytical Methods 16%
• Active Metabolite 16%
• Anticancer Drugs 16%
• Sample Pretreatment 16%
• Tyrosine Kinase Inhibitor 16%
• Validation Studies 16%
• Acetonitrile 16%
• Isotopically Labeled 16%
• Labeled Compounds 16%
• Multiple Reaction Monitoring 16%
• Monitoring Service 16%
• Plasma Volume 16%
• Analyte Quantification 16%
• Monitoring Environment 16%

Pharmacology, Toxicology and Pharmaceutical Science

• Therapeutic Drug Monitoring 100%
• Phosphotransferase Inhibitor 100%
• Sunitinib 66%
• Dasatinib 33%
• Erlotinib 33%
• Sorafenib 33%
• Imatinib 33%
• Vemurafenib 33%
• Nilotinib 33%
• Pazopanib 33%
• Gefitinib 33%
• Lapatinib 33%
• Acetonitrile 16%
• Active Metabolite 16%
• Protein Tyrosine Kinase Inhibitor 16%